

From: [Tracy Du](#)
To: [AGO - High Cost Prescription Drugs](#)
Subject: New Drug Product WAC Information
Date: Friday, January 17, 2020 2:01:09 PM
Attachments: [image001.png](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To whom it concerns,

AYVAKIT™ (avapritinib) was introduced to the market on January 16, 2020 . AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. The anticipated annual patient population in the United States for this ultra-rare orphan indication is no more than a couple hundred patients.

Please see below for the brief information related to AYVAKIT™ and detail information will be submitted by February 16, 2020:

NDC	Product Name	Price
72064-0110-30	AYVAKIT™(avapritinib) Tablets 100 MG	\$32,000.00
72064-0120-30	AYVAKIT™(avapritinib) Tablets 200 MG	\$32,000.00
72064-0130-30	AYVAKIT™(avapritinib) Tablets 300 MG	\$32,000.00

Please contact me with any questions concerns.

Sincerely,

Tracy Du



Tracy Du
Director of Accounting
45 Sidney Street
Cambridge, MA 02139
Phone: 857-209-3092

CONFIDENTIALITY NOTICE: This electronic mail transmission may contain privileged, confidential and/or sensitive information and is intended only for the review of the party to whom it is addressed and for the stated purpose. Unauthorized use or disclosure is strictly prohibited. If you have received this transmission in error, please notify privacy@blueprintmedicines.com and immediately delete the transmission without reading its contents.